bd 1047 has been researched along with Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appleyard, MV; Box, G; Campbell, LA; Cooper, MA; Downes, CP; Eccles, S; Ferguson, MJ; Hayes, A; Howie, J; Lambert, JJ; Leslie, NR; McLean, D; McTavish, N; Murray, K; Nutley, B; O'Neill, M; Peters, JA; Prescott, AR; Raynaud, F; Safrany, ST; Samson, J; Spruce, BA; Thompson, AM; Watt, S | 1 |
1 other study(ies) available for bd 1047 and Breast Cancer
| Article | Year |
|---|---|
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcium Signaling; Carbazoles; Caspases; Cattle; Cell Division; Cell Line, Tumor; Enzyme Activation; Ethylenediamines; Haloperidol; Humans; Isoenzymes; Lung Neoplasms; Male; Mice; Mice, Nude; Phospholipase C delta; Piperazines; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, sigma; Sigma-1 Receptor; Type C Phospholipases; Xenograft Model Antitumor Assays | 2004 |